vs
Side-by-side financial comparison of Burke & Herbert Financial Services Corp. (BHRB) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $86.5M, roughly 1.1× Burke & Herbert Financial Services Corp.). Burke & Herbert Financial Services Corp. runs the higher net margin — 34.9% vs 25.0%, a 9.9% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs 4.9%). Burke & Herbert Financial Services Corp. produced more free cash flow last quarter ($96.2M vs $12.8M). Over the past eight quarters, Burke & Herbert Financial Services Corp.'s revenue compounded faster (81.1% CAGR vs 34.6%).
Burke & Herbert Financial Services Corp is a U.S.-based regional financial holding company, offering personal and commercial banking, wealth management, residential mortgage lending, and small business financing services. Its core market covers Virginia and adjacent Mid-Atlantic regions, serving retail consumers, SMEs, and high-net-worth clients.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
BHRB vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.5M | $92.9M |
| Net Profit | $30.2M | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | 43.8% | 24.1% |
| Net Margin | 34.9% | 25.0% |
| Revenue YoY | 4.9% | 23.3% |
| Net Profit YoY | 52.8% | 17.3% |
| EPS (diluted) | $1.98 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.5M | $92.9M | ||
| Q3 25 | $85.4M | $67.5M | ||
| Q2 25 | $87.1M | $63.2M | ||
| Q1 25 | $83.0M | $52.6M | ||
| Q4 24 | $82.5M | $75.4M | ||
| Q3 24 | $83.8M | $57.9M | ||
| Q2 24 | $69.3M | $52.7M | ||
| Q1 24 | $26.4M | $51.3M |
| Q4 25 | $30.2M | $23.2M | ||
| Q3 25 | $30.0M | $5.1M | ||
| Q2 25 | $29.9M | $-553.0K | ||
| Q1 25 | $27.2M | $-11.2M | ||
| Q4 24 | $19.8M | $19.8M | ||
| Q3 24 | $27.6M | $-901.0K | ||
| Q2 24 | $-16.9M | $-4.7M | ||
| Q1 24 | $5.2M | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
| Q4 25 | 43.8% | 24.1% | ||
| Q3 25 | 43.3% | 5.1% | ||
| Q2 25 | 42.7% | -3.2% | ||
| Q1 25 | 39.6% | -24.3% | ||
| Q4 24 | 24.6% | 24.5% | ||
| Q3 24 | 39.2% | -4.3% | ||
| Q2 24 | -27.5% | -11.5% | ||
| Q1 24 | 22.3% | -10.7% |
| Q4 25 | 34.9% | 25.0% | ||
| Q3 25 | 35.1% | 7.5% | ||
| Q2 25 | 34.3% | -0.9% | ||
| Q1 25 | 32.8% | -21.4% | ||
| Q4 24 | 24.0% | 26.3% | ||
| Q3 24 | 33.0% | -1.6% | ||
| Q2 24 | -24.4% | -8.9% | ||
| Q1 24 | 19.8% | -7.5% |
| Q4 25 | $1.98 | $0.46 | ||
| Q3 25 | $1.97 | $0.10 | ||
| Q2 25 | $1.97 | $-0.01 | ||
| Q1 25 | $1.80 | $-0.23 | ||
| Q4 24 | $1.72 | $0.40 | ||
| Q3 24 | $1.82 | $-0.02 | ||
| Q2 24 | $-1.41 | $-0.10 | ||
| Q1 24 | $0.69 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $854.6M | $354.6M |
| Total Assets | $7.9B | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $135.4M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | — | $116.2M | ||
| Q3 24 | — | $101.7M | ||
| Q2 24 | — | $102.5M | ||
| Q1 24 | — | $110.6M |
| Q4 25 | $854.6M | $354.6M | ||
| Q3 25 | $822.2M | $321.9M | ||
| Q2 25 | $780.0M | $306.8M | ||
| Q1 25 | $758.0M | $295.5M | ||
| Q4 24 | $730.2M | $292.0M | ||
| Q3 24 | $738.1M | $257.5M | ||
| Q2 24 | $693.1M | $243.0M | ||
| Q1 24 | $319.3M | $233.9M |
| Q4 25 | $7.9B | $488.0M | ||
| Q3 25 | $7.9B | $453.3M | ||
| Q2 25 | $8.1B | $435.6M | ||
| Q1 25 | $7.8B | $424.6M | ||
| Q4 24 | $7.8B | $432.7M | ||
| Q3 24 | $7.9B | $390.4M | ||
| Q2 24 | $7.8B | $376.8M | ||
| Q1 24 | $3.7B | $356.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $107.9M | $15.0M |
| Free Cash FlowOCF − Capex | $96.2M | $12.8M |
| FCF MarginFCF / Revenue | 111.2% | 13.8% |
| Capex IntensityCapex / Revenue | 13.5% | 2.4% |
| Cash ConversionOCF / Net Profit | 3.57× | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $164.1M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $107.9M | $15.0M | ||
| Q3 25 | $39.3M | $22.1M | ||
| Q2 25 | $41.0K | $8.2M | ||
| Q1 25 | $37.6M | $6.6M | ||
| Q4 24 | $85.8M | $22.2M | ||
| Q3 24 | $47.8M | $10.2M | ||
| Q2 24 | $-46.0M | $18.5M | ||
| Q1 24 | $7.1M | $7.2M |
| Q4 25 | $96.2M | $12.8M | ||
| Q3 25 | $35.4M | $19.5M | ||
| Q2 25 | $-3.4M | $81.0K | ||
| Q1 25 | $35.9M | $-7.6M | ||
| Q4 24 | $81.2M | $8.5M | ||
| Q3 24 | $46.0M | $-9.2M | ||
| Q2 24 | $-47.0M | $1.8M | ||
| Q1 24 | $5.6M | $-6.8M |
| Q4 25 | 111.2% | 13.8% | ||
| Q3 25 | 41.5% | 28.8% | ||
| Q2 25 | -3.9% | 0.1% | ||
| Q1 25 | 43.2% | -14.5% | ||
| Q4 24 | 98.5% | 11.2% | ||
| Q3 24 | 55.0% | -15.9% | ||
| Q2 24 | -67.8% | 3.4% | ||
| Q1 24 | 21.2% | -13.3% |
| Q4 25 | 13.5% | 2.4% | ||
| Q3 25 | 4.5% | 3.9% | ||
| Q2 25 | 3.9% | 12.9% | ||
| Q1 25 | 2.1% | 27.0% | ||
| Q4 24 | 5.5% | 18.3% | ||
| Q3 24 | 2.1% | 33.5% | ||
| Q2 24 | 1.5% | 31.8% | ||
| Q1 24 | 5.7% | 27.3% |
| Q4 25 | 3.57× | 0.65× | ||
| Q3 25 | 1.31× | 4.35× | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 1.38× | — | ||
| Q4 24 | 4.33× | 1.12× | ||
| Q3 24 | 1.73× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.36× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHRB
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
